-
Product Insights
Aviation Logis – Long Xa Logistics Port – Bac Giang
Equip yourself with the essential tools needed to make informed and profitable decisions with our Aviation Logis - Long Xa Logistics Port - Bac Giang report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
DPI Hai Phong – Hoang Xa Residential Development – Hai Phong
Equip yourself with the essential tools needed to make informed and profitable decisions with our DPI Hai Phong - Hoang Xa Residential Development - Hai Phong report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
MoT Vietnam – Go Dau – Xa Mat Expressway Upgrade Phase I – Tay Ninh
Equip yourself with the essential tools needed to make informed and profitable decisions with our MoT Vietnam - Go Dau - Xa Mat Expressway Upgrade Phase I - Tay Ninh report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash...
-
Product Insights
Hai Phong City – Kien Thuy Industrial Park – Doan Xa Commune Coastal Road – Hai Phong
Equip yourself with the essential tools needed to make informed and profitable decisions with our Hai Phong City - Kien Thuy Industrial Park - Doan Xa Commune Coastal Road - Hai Phong report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our...
-
Company Profile
Catalyst Biosciences Inc – Company Profile
Gyre Therapeutics Inc (Gyre Therapeutics), formerly Catalyst Biosciences Inc, is a clinical-stage biopharmaceutical company. It develops protease-based advanced medicines to treat hematological indications. The company specializes in hemostasis and subcutaneous prophylaxis of hemophilia and surgery, and anti-complement. Its pipeline products include factor vIIa marzeptacog alfa, for the treatment of individuals with hemophilia A and B; factor IX CB 2679d, for the treatment of hemophilia B; factor Xa variants and anti-C3: CB 2782, for treating dry age-related macular degeneration, ischemia-reperfusion injuries...
Add to Basket -
Product Insights
Hematology Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Hematology Pipeline Market Report Overview Hematology tests evaluate numerous conditions involving blood and its components and the tests that generate results immediately and can be done in a limited resource setting. The hematology pipeline market research report provides comprehensive information about the hematology pipeline reconstruction with a comparative analysis of the reconstruction at various stages of development and information about the clinical trials which are in progress. Key Segments ·      Immunohematology ·      Hematology Reagents ·      Hemostasis Calibrators and Controls ·      ...
-
Company Profile
Portola Pharmaceuticals LLC – Company Profile
Portola Pharmaceuticals LLC (Portola Pharmaceuticals) is a biopharmaceutical company that discovers, and develops therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. The company's products portfolio include Betrixaban, an oral once-daily Factor Xa inhibitor anticoagulant that inhibits the activity of Factor Xa; andexanet alfa, a recombinant protein designed to reverse anticoagulant activity of both direct and indirect Factor Xa inhibitors; and cerdulatinib, an oral, dual Syk-JAK inhibitor in development to treat hematologic cancers. Portola Pharmaceuticals provides compounds using...
Add to Basket -
Product Insights
Quarterly Hot Tea pricing trends in Brazil
Consumers' preferences for stores are most heavily influenced by pricing and promotions, but brands and retailers continue to adjust prices and promotions based on insufficient information from expensive, drawn-out, and incomplete audits of rival techniques. Brands and retailers can benefit from the unique intelligence provided by GlobalData Ecommerce Price Tracker, covering millions of SKUs, to identify, anticipate, and implement important business choices. GlobalData's new report titled "Quarterly Hot Tea pricing trends in Brazil" serves as a crucial resource for analyzing...
-
Product Insights
Net Present Value Model: Ondexxya
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Ondexxya Drug Details Andexanet alfa (PRT4445,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – rivaroxaban
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry rivaroxaban Drug Details Rivaroxaban is under development for the treatment of antiphospholipid syndrome. The...